Clinical Trials
6 trialsNCT02296918 2025-12-19
Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL
Acerta Pharma BV
Phase 1 Completed
NCT01076556 2015-11-11
Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00612612 2013-09-30
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00176475 2013-09-17
Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
Rutgers, The State University of New Jersey
Phase 1 Terminated
NCT00098488 2013-06-04
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00080925 2012-03-08
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Completed